Literature DB >> 19470891

Vascular regeneration by local growth factor release is self-limited by microvascular clearance.

Kha N Le1, Chao-Wei Hwang, A Rami Tzafriri, Mark A Lovich, Alison Hayward, Elazer R Edelman.   

Abstract

BACKGROUND: The challenge of angiogenesis science is that stable sustained vascular regeneration in humans has not been realized despite promising preclinical findings. We hypothesized that angiogenic therapies powerfully self-regulate by dynamically altering tissue characteristics. Induced neocapillaries increase drug clearance and limit tissue retention and subsequent angiogenesis even in the face of sustained delivery. METHODS AND
RESULTS: We quantified how capillary flow clears fibroblast growth factor after local epicardial delivery. Fibroblast growth factor spatial loading was significantly reduced with intact coronary perfusion. Penetration and retention decreased with transendothelial permeability, a trend diametrically opposite to intravascular delivery, in which factor delivery depends on vascular leak, but consistent with a continuum model of drug transport in perfused tissues. Model predictions of fibroblast growth factor sensitivity to manipulations of its diffusivity and transendothelial permeability were validated by conjugation to sucrose octasulfate. Induction of neocapillaries adds pharmacokinetic complexity. Sustained local fibroblast growth factor delivery in vivo produced a burst of neovascularization in ischemic myocardium but was followed by drug washout and a 5-fold decrease in fibroblast growth factor penetration depth.
CONCLUSIONS: The very efficacy of proangiogenic compounds enhances their clearance and abrogates their pharmacological benefit. This self-limiting property of angiogenesis may explain the failures of promising proangiogenic therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470891      PMCID: PMC2764268          DOI: 10.1161/CIRCULATIONAHA.108.823609

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

Review 1.  Microvascular permeability.

Authors:  C C Michel; F E Curry
Journal:  Physiol Rev       Date:  1999-07       Impact factor: 37.312

2.  NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study.

Authors:  Mariann Gyöngyösi; Aliasghar Khorsand; Sholeh Zamini; Wolfgang Sperker; Christoph Strehblow; Jens Kastrup; Eric Jorgensen; Birger Hesse; Kristina Tägil; Hans Erik Bøtker; Witold Ruzyllo; Anna Teresiñska; Dariusz Dudek; Alicja Hubalewska; Andreas Rück; Søren Steen Nielsen; Senta Graf; Gerald Mundigler; Jacek Novak; Heinz Sochor; Gerald Maurer; Dietmar Glogar; Christer Sylven
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

3.  Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury.

Authors:  Ivan Rubio-Gayosso; Steven H Platts; Brian R Duling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-01-06       Impact factor: 4.733

4.  Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.

Authors:  D J Stewart; J D Hilton; J M O Arnold; J Gregoire; A Rivard; S L Archer; F Charbonneau; E Cohen; M Curtis; C E Buller; F O Mendelsohn; N Dib; P Page; J Ducas; S Plante; J Sullivan; J Macko; C Rasmussen; P D Kessler; H S Rasmussen
Journal:  Gene Ther       Date:  2006-06-22       Impact factor: 5.250

5.  Drug delivery models transported to a new level.

Authors:  E R Edelman; M Lovich
Journal:  Nat Biotechnol       Date:  1998-02       Impact factor: 54.908

6.  START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.

Authors:  Niels van Royen; Stephan H Schirmer; Bektas Atasever; Casper Y H Behrens; Dirk Ubbink; Eva E Buschmann; Michiel Voskuil; Pieter Bot; Imo Hoefer; Reinier O Schlingemann; Bart J Biemond; J G Tijssen; Christoph Bode; Wolfgang Schaper; Jacques Oskam; Dink A Legemate; Jan J Piek; Ivo Buschmann
Journal:  Circulation       Date:  2005-08-08       Impact factor: 29.690

7.  Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.

Authors:  M J Gounis; M-G Spiga; R M Graham; A Wilson; S Haliko; B B Lieber; A K Wakhloo; K A Webster
Journal:  Gene Ther       Date:  2005-05       Impact factor: 5.250

8.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.

Authors:  Matthew R Dreher; Wenge Liu; Charles R Michelich; Mark W Dewhirst; Fan Yuan; Ashutosh Chilkoti
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

9.  Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution.

Authors:  D F Lazarous; M Shou; J A Stiber; D M Dadhania; V Thirumurti; E Hodge; E F Unger
Journal:  Cardiovasc Res       Date:  1997-10       Impact factor: 10.787

10.  Effect of basic fibroblast growth factor on angiogenesis in the infarcted porcine heart.

Authors:  E Watanabe; D M Smith; J Sun; F W Smart; J B Delcarpio; T B Roberts; C H Van Meter; W C Claycomb
Journal:  Basic Res Cardiol       Date:  1998-02       Impact factor: 17.165

View more
  7 in total

1.  Local epicardial inotropic drug delivery allows targeted pharmacologic intervention with preservation of myocardial loading conditions.

Authors:  Mark A Lovich; Abraham E Wei; Mikhail Y Maslov; Peter I Wu; Elazer R Edelman
Journal:  J Pharm Sci       Date:  2011-06-30       Impact factor: 3.534

Review 2.  Clinical translation of controlled protein delivery systems for tissue engineering.

Authors:  Kara L Spiller; Gordana Vunjak-Novakovic
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

3.  Myocardial drug distribution generated from local epicardial application: potential impact of cardiac capillary perfusion in a swine model using epinephrine.

Authors:  Mikhail Y Maslov; Elazer R Edelman; Matthew J Pezone; Abraham E Wei; Matthew G Wakim; Michael R Murray; Hisashi Tsukada; Iraklis S Gerogiannis; Adam Groothuis; Mark A Lovich
Journal:  J Control Release       Date:  2014-09-16       Impact factor: 9.776

4.  High concentrations of drug in target tissues following local controlled release are utilized for both drug distribution and biologic effect: an example with epicardial inotropic drug delivery.

Authors:  Mikhail Y Maslov; Elazer R Edelman; Abraham E Wei; Matthew J Pezone; Mark A Lovich
Journal:  J Control Release       Date:  2013-07-18       Impact factor: 9.776

Review 5.  Therapeutic angiogenesis: controlled delivery of angiogenic factors.

Authors:  Hunghao Chu; Yadong Wang
Journal:  Ther Deliv       Date:  2012-06

6.  Genetic susceptibility of five tagSNPs in the endothelin-1 (EDN1) gene to coronary artery disease in a Chinese Han population.

Authors:  Li-Li Liang; Lin Chen; Meng-Yuan Zhou; Meng-Yun Cai; Jie Cheng; Yi Chen; Si-Kun You; Lin-Bin Chen; Zi-Bin Tang; Xi-Li Yang; Can Chen; Xinguang Liu; Xing-Dong Xiong
Journal:  Biosci Rep       Date:  2018-10-17       Impact factor: 3.840

7.  Assessment of the Angiogenic Potential of 2-Deoxy-D-Ribose Using a Novel in vitro 3D Dynamic Model in Comparison With Established in vitro Assays.

Authors:  Serkan Dikici; Betül Aldemir Dikici; Shirin Issa Bhaloo; Mercedes Balcells; Elazer R Edelman; Sheila MacNeil; Gwendolen C Reilly; Colin Sherborne; Frederik Claeyssens
Journal:  Front Bioeng Biotechnol       Date:  2020-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.